Viva Biotech
334 Aidisheng Rd, Zhangjiang High-Tech Park, Shanghai, 201203, China
Overview
Viva Biotech offers global innovative drug R&D companies one-stop comprehensive services ranging from early structure-based drug R&D to commercial drug delivery. Using its advantages in the field of structure-based drug discovery (SBDD) technology, it provides global partners with CRO services in the new drug research stage and has established X-ray protein crystal technology, cryo-electron microscopy (Cryo-EM), and affinity mass spectrometry screening technology (ASMS), surface plasmon resonance (SPR), hydrogen-deuterium exchange mass spectrometry (HDX-MS), computer-aided drug design, and other advanced technology platforms.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Clinical Trials
- Health Care
- Medical
Investment portfolio
- Totient
Participated · Seed · Sep 2020
Totient operates an AI-driven platform that leverages tertiary lymphoid structures (TLSs) to identify tissue-specific antigens and reconstruct high-affinity human antibodies from affected tissues. The company mines samples from patients with exceptional immune responses, beginning with a population of over 50,000 samples, and has reconstructed antibodies against known and novel extracellular oncology targets such as GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, and GPR83. Its human-derived antibodies are highly specific to tissue-specific antigens and are positioned for development as cell therapies, antibody-drug conjugates (ADCs), and bispecifics. Totient emerged from stealth concurrent with a $10M seed financing, which provides initial capital to advance its discovery pipeline. The company has adapted its platform to discover COVID-19 antibodies and announced a collaboration with Ginkgo Bioworks to reconstruct anti‑SARS‑CoV‑2 antibodies from bronchoalveolar lavage fluid (BALF) samples. Focusing on BALF samples aims to access a previously unexplored source of therapeutic candidates beyond typical blood-derived efforts.
- Mebias Discovery
Led · Equity · Oct 2019
Mebias Discovery develops GPCR-targeted drugs using a platform designed to avoid on-target adverse effects by achieving signaling-pathway selectivity. Led by Lawrence Kuo, PhD, the company’s discovery approach centers on native GPCR purification and 19F-protein nuclear magnetic resonance. The company intends to expand its pipeline into gastrointestinal and inflammation programs, applying its platform to discover drugs that avoid on-target side effects. Current programs include pathway-selective motilin receptor agonists for gastric motility disorders and S1P1-targeted candidates for pain and neuroinflammation. Its lead mu-opioid program has produced compounds that in preclinical models provide analgesia without respiratory depression, constipation, or addiction potential. That program is supported by a five-year UG3/UH3 grant from the National Institute on Drug Abuse and investment from Bioadvance; the company recently closed a $3.5M funding round.